Pfizer agreed to pay almost $60 million to resolve allegations that its Biohaven Prescription drugs unit paid kickbacks to entice physicians to prescribe a migraine therapy. The alleged violations occurred earlier than Pfizer purchased the corporate three years in the past, in keeping with the U.S. Division of Justice.
The authorities alleged that, from March 2020 by September 2022, Biohaven improperly paid docs talking charges and for meals at “excessive finish” eating places with a purpose to persuade them to prescribe Nurtec ODT, the centerpiece of the $11.6 billion acquisition. The yr earlier than, the medicine generated $462.5 million in gross sales.
The Justice Division additionally claimed that sure docs who attended a number of applications about the identical matter didn’t really obtain any instructional profit from doing so. As well as, the applications had been attended by folks with “no instructional must attend, such because the audio system’ spouses, relations, or mates, or colleagues from the audio system’ personal medical apply.”
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
